Takeda (TAK) Q2 FY25 earnings call

Takeda's Q2 FY25 results confirm business fundamentals are tracking as planned, despite the peak impact of VYVANSE generic erosion. The company is poised for a new business cycle from FY26, driven by an accelerating late-stage pipeline, including positive Phase III data for oveporexton and rusfertide, and a transformative oncology partnership with Innovent Biologics. While transactional FX headwinds impacted profit guidance, Takeda maintains tight OpEx control and a progressive dividend policy, positioning for long-term growth and margin improvement.